Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 217 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Difficile Clear all
Not yet recruiting Early Phase 1 Interventional

Pilot Trial of Xylitol for C. Difficile De-Colonization in Patients With Inflammatory Bowel Disease

NCT06799039
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Clostridioides Difficile Infection
Interventions
Xylitol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 21, 2026, 7:20 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection

NCT04781387
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
CRS3123, Active Comparator
Drug
Lead sponsor
Crestone, Inc
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
18
States / cities
Fullerton, California • Lancaster, California • Mission Hills, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 21, 2026, 7:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Trial of a Single Dose of CRS3123

NCT01551004
View directory record Official record
Conditions
Clostridium Difficile Colitis
Interventions
CRS3123, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 21, 2026, 7:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123.

NCT02106338
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Placebo, CRS3123
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Oct 21, 2026, 7:20 AM EDT
Recruiting Phase 2 Interventional

ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection

NCT07513285
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
Ibezapolstat
Drug
Lead sponsor
Acurx Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
19
States / cities
Sacramento, California • Hamden, Connecticut • Coral Gables, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 7:20 AM EDT
Completed Phase 2 Interventional Results available

Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease

NCT00350298
View directory record Official record
Conditions
Clostridium Infections
Interventions
GS-CDA1/MDX-1388, normal saline
Biological
Lead sponsor
MassBiologics
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
22
States / cities
Los Angeles, California • Oakland, California • Newark, Delaware + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Oct 21, 2026, 7:20 AM EDT
Completed Phase 1 Interventional

Treatment of Recurrent Clostridium Difficile Infection With RBX7455

NCT02981316
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
RBX7455
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 21, 2026, 7:20 AM EDT
Withdrawn Phase 4 Interventional

Addition of Lactobacillus to Metronidazole in Treatment of CDAD

NCT00304863
View directory record Official record
Conditions
Enterocolitis, Pseudomembranous Colitis, Antibiotic-associated Colitis
Interventions
Lactobacillus GG
Drug
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 21, 2026, 7:20 AM EDT
Not yet recruiting Phase 1 Interventional

Xylitol Use for Decolonization of C. Difficile in Patients With IBD

NCT05852587
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Clostridioides Difficile Infection
Interventions
Xylitol, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 21, 2026, 7:20 AM EDT
Completed Phase 3 Interventional Results available

ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection

NCT03183141
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
SER-109
Biological
Lead sponsor
Seres Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
97
States / cities
Dothan, Alabama • Sun City West, Arizona • Mather, California + 84 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 21, 2026, 7:20 AM EDT
Not listed Phase 2 Interventional

An Exploratory, Open-Label, Oligo-Center Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravenous DNV3837 in Subjects With Clostridium Difficile Infection

NCT03988855
View directory record Official record
Conditions
Clostridium Difficile (C. Difficile)
Interventions
DNV3837
Drug
Lead sponsor
Deinove
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
10
States / cities
Anniston, Alabama • Sacramento, California • Idaho Falls, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 21, 2026, 7:20 AM EDT
Withdrawn Not applicable Interventional

Extended Treatment With Vancomycin for Clostridium Difficile Colitis

NCT00861887
View directory record Official record
Conditions
Clostridium Difficile Colitis
Interventions
Standard Vancomycin, Extended Vancomycin
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 21, 2026, 7:20 AM EDT
Completed Phase 1 Interventional

An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon Resection

NCT06692179
View directory record Official record
Conditions
Recurrent Clostridioides Difficile Infection, Colonic Surgery
Interventions
Orally administered preparation of fecal microbiota (MTP-101P)
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 21, 2026, 7:20 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH)

NCT03005379
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Fecal Microbiota Therapy (FMT), Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 21, 2026, 7:20 AM EDT
Enrolling by invitation Phase 1 Interventional

Defined Fecal Microbiota Transplantation for Clostridium Difficile Diarrhea

NCT01868373
View directory record Official record
Conditions
Active C. Difficile Colitis
Interventions
Microbiota Transplantation (FMT)
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2036
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 21, 2026, 7:20 AM EDT
Completed Phase 4 Interventional

Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial

NCT02462590
View directory record Official record
Conditions
Ventilator Associated Pneumonia, Infections, C-Difficile, Antibiotic-associated Diarrhea, Diarrhea
Interventions
L. rhamnosus GG - Probiotic, Placebo - Microcrystalline Cellulose
Drug
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Enrollment
2,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Rochester, Minnesota • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 21, 2026, 7:20 AM EDT
Completed No phase listed Observational

Vancomycin vs. Nitazoxanide to Treat Recurrent C. Difficile Colitis

NCT00304889
View directory record Official record
Conditions
Clostridium Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
Interventions
Not listed
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 21, 2026, 7:20 AM EDT
Completed Not applicable Interventional Results available

Safety of Stool Transplant for Patients With Difficult to Treat C. Difficile Infection

NCT02770326
View directory record Official record
Conditions
C. Difficile Infection, Cancer
Interventions
Fecal Microbiota Transplantation (FMT)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 21, 2026, 7:20 AM EDT
Completed Phase 4 Interventional

Animal-Assisted Visitation Program Chlorhexidine Trial

NCT04171817
View directory record Official record
Conditions
Methicillin-resistant Staphylococcus Aureus, Clostridium Difficile, Pseudomonas Aeruginosa
Interventions
Chlorhexidine
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
3 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Baltimore, Maryland • St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 7:20 AM EDT
Completed Phase 4 Interventional Results available

TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment

NCT03388268
View directory record Official record
Conditions
Clostridium Difficile Infection, Diarrhea
Interventions
Oral Vancomycin, Placebo, Toxin enzyme immunoassay, Nuceleic acid amplification test
Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Oct 21, 2026, 7:20 AM EDT
Terminated Phase 1 Interventional

Probiotics in the Reduction of Antibiotic Associated Diarrhea

NCT02589964
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Florajen-3, Placebo
Dietary Supplement · Other
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years to 120 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Oct 21, 2026, 7:20 AM EDT
Recruiting Phase 2Phase 3 Interventional

Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients

NCT07221370
View directory record Official record
Conditions
Clostridium Difficile Infection, Vancomycin Resistant Enterococci Infection
Interventions
Vancomycin 125mg, Placebo
Drug
Lead sponsor
Riverside University Health System Medical Center
Other
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Moreno Valley, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 21, 2026, 7:20 AM EDT
Terminated Phase 2 Interventional Results available

The Clostridioides Difficile Trial of REC-3964

NCT06536465
View directory record Official record
Conditions
Recurrent Clostridioides Difficile Infection
Interventions
REC-3964
Drug
Lead sponsor
Recursion Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 115 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Toms River, New Jersey • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 21, 2026, 7:20 AM EDT
Completed Phase 4 Interventional Results available

Screening to Prophylax Against Clostridium Difficile Infection -

NCT02996487
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Vancomycin, Placebo
Drug · Other
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
1,294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
3
States / cities
Dearborn, Michigan • Royal Oak, Michigan • Troy, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 21, 2026, 7:20 AM EDT